Jefferies raised the firm’s price target on Neurocrine (NBIX) to $189 from $177 and keeps a Buy rating on the shares. Data is imminent from NBI-‘568’s Phase 2 study in schizophrenia and the firm’s analysis suggests ‘568 could show emraclidine-like efficacy with better safety compared to Bristol Myers’ (BMY) KarXT and similar to AbbVie’s (ABBV) emraclidine, the analyst tells investors. The firm models risk-adj peak sales of $1.8B for ‘568 in schizophrenia, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $167 from $164 at Canaccord
- Neurocrine price target raised to $180 from $157 at Baird
- Neurocrine price target raised to $180 from $169 at Barclays
- Neurocrine price target raised to $190 from $160 at H.C. Wainwright
- Neurocrine raises FY24 INGREZZA net product sales view to $2.25B-$2.3B